BrainScope

Coming – September 9

Why UFC Is Working With BrainScope To Protect Athletes

Date and Time

September 9

–

12:00 PM ET 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

BrainScope is revolutionizing brain health diagnostics by applying AI to brain electrical activity (EEG). They have developed the first AI-enabled neurology device ever cleared by the FDA and hold a significant first-mover advantage in this space.

BrainScope’s technology is so promising, the UFC Performance Institute is supporting its fighters by piloting it for the objective assessment of brain bleeds and concussions. UFC Performance Institute sought BrainScope out with a focus on fighter health seeking to reduce the risk of CTE from repeated head impacts.

Their device can be used to conduct a BrainScope concussion assessment before and after a fight, game, training, or season to objectively measure an athlete’s individual change. There is no way to “cheat” the BrainScope test, as it applies AI to brain EEG. The same 10–15-minute assessment can also rule out the likelihood of a brain bleed with 99% sensitivity, detecting even the smallest amount of blood visible on a head CT scan (1cc).

BrainScope’s point-of-care brain bleed and concussion assessment technology has been clinically validated through 29 clinical studies, 8 FDA clearances, and 35 peer-reviewed publications—including 2 in JAMA. The Concussion Index biomarker development and 50-site FDA clinical study were funded through a $10 million DoD research contract and two awards from the NFL and GE, as an original recipient and final winner of their Head Health Challenge I.

Join our Fireside Chat with BrainScope CEO, Laurie Silver, to hear more about their partnership with the UFC Performance Institute and how their technology is also helping improve the diagnosis and treatment of other neurological conditions including stroke, Alzheimer’s, and other clinical trial services.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.